Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.75 USD
Change Today 0.00 / 0.00%
Volume 1.0K
POLXF On Other Exchanges
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

polydex pharmaceuticals ltd (POLXF) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/6/14 - $1.28
52 Week Low
11/10/14 - $0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

polydex pharmaceuticals ltd (POLXF) Related Businessweek News

No Related Businessweek News Found

polydex pharmaceuticals ltd (POLXF) Details

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market; and manufacture of bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. The company primarily offers Dextran and derivative products, including Iron Dextran, a derivative of Dextran used for the treatment of anemia in pigs; and Dextran Sulphate, a specialty chemical derivative of Dextran used in research applications by the pharmaceutical industry and other centers of chemical research. Polydex Pharmaceuticals Limited company sells its Iron Dextran primarily to independent distributors and wholesalers in Europe, the Far East, South America, and Canada; and Dextran Sulphate to the independent distributors and wholesalers in the United States and Europe for analytical applications. It also develops Ushercell, a high molecular weight Cellulose Sulphate envisioned for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4 for the treatment of Cystic fibrosis, a genetic disease. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. The company was founded in 1966 and is based in Toronto, Canada.

21 Employees
Last Reported Date: 04/21/14
Founded in 1966

polydex pharmaceuticals ltd (POLXF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

polydex pharmaceuticals ltd (POLXF) Key Developments

Polydex Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2014

Polydex Pharmaceuticals Ltd. reported earnings results for the third quarter and nine months ended October 31, 2014. For the quarter, the company reported sales of $1,301,083 against $1,319,100 a year ago. Net income was $104,653 or $0.03 per basic and diluted share against net income of $46,300 or $0.01 per basic and diluted share a year ago. EBITDA (Earnings before interest, taxes, depreciation and amortization) increased to $183,944 compared to $93,669 for the same period in the previous year. For the nine months, the company reported sales of $3,984,288 against $4,625,497 a year ago. Net income was $238,388 or $0.07 per diluted share against net income of $518,594 or $0.15 per diluted share a year ago. EBITDA was $416,348.

Polydex Pharmaceuticals Limited Announces Earnings Results for the Second Quarter and Six Months Ended July 31, 2014

Polydex Pharmaceuticals Limited announced earnings results for the second quarter and six months ended July 31, 2014. For the quarter, the company reported sales was USD 1,270,223 against USD 1,866,253 a year ago. Net income was USD 59,151 against USD 200,792 a year ago. Diluted earnings per share were USD 0.02 against USD 0.06 a year ago. EBITDA for the fiscal second quarter amounted to USD 114,715. For the six months, the company reported sales was USD 2,683,205 against USD 3,306,397 a year ago. Net income was USD 133,739 against USD 472,301 a year ago. Diluted earnings per share were USD 0.04 against USD 0.14 a year ago. EBITDA amounted to USD 238,692 for the six-month period ended July 31, 2014. The company invested in excess of USD 340,000 into production equipment upgrades during the period.

Polydex Pharmaceuticals Ltd., Annual General Meeting, Jul 30, 2014

Polydex Pharmaceuticals Ltd., Annual General Meeting, Jul 30, 2014., at 11:00 Eastern Daylight. Location: at 421Comstock Road. Agenda: To elect one director to the company's board of directors, the name of whom is set forth in the accompanying proxy statement, to serve until the annual general meeting of the members in 2017 or until their successors are elected; to ratify the appointment of Schwartz Levitsky Feldman LLP as the independent accountants of the company; and to transact such further or other business as may properly come before the meeting or any adjournment or adjournments thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POLXF:US $0.75 USD 0.00

POLXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for POLXF.
View Industry Companies

Industry Analysis


Industry Average

Valuation POLXF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POLYDEX PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at